Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.

NCT00251966 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00251966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00251966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2004
Completion date
September 30, 2005
Enrollment
960
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux